5290 |
PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA |
PIK3CA |
CLOVE |
CWS5 |
MCAP |
MCM |
MCMTC |
PI3K |
PI3K-alpha |
p110-alpha |
171834 |
8975 |
ENSG00000121879 |
OTTHUMG00000157311 |
5289 |
P42336 |
PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT, ALPHA ISOFORM (EC 2.7.1.153) (PI3-KINASE P110 SUBUNIT ALPHA) (PTDINS- 3-KINASE P110) (PI3K). [SOURCE:UNIPROT/SWISSPROT;ACC:P42336] |
37 |
PA33308 |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform |
Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha |
Phosphoinositide-3-kinase catalytic alpha polypeptide |
Serine/threonine protein kinase PIK3CA |
PI3-kinase subunit alpha |
PI3Kalpha |
PtdIns-3-kinase subunit alpha |
PtdIns-3-kinase subunit p110-alpha |
p110alpha |
PK3CA_HUMAN |
PI3-kinase alpha |
T80276 |
CLAPO |
CCM4 |
CancerCommons Reported Gene Name | PI3K |
CancerCommons Reported Gene Name | PI3K/mTOR |
Human Readable Name | DRUGGABLE GENOME |
Target Class | Enzymes |
Target Subclass | EC:2.7.1.153 |
Interpro Short Name | PI3/4_kinase_cat_dom |
Human Readable Name | PHOSPHATIDYLINOSITOL 3 KINASE |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Acc | IPR000403 |
Uniprot Status | Swiss-Prot |
Interpro Type | Domain |
Interpro Name | Phosphatidylinositol 3-/4-kinase, catalytic domain |
Gene Biotype | PROTEIN_CODING |
KINASE |
SERINE THREONINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
PHOSPHATIDYLINOSITOL 3 KINASE |
CLINICALLY ACTIONABLE |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Phase I |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase p110-alpha subunit inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Indication/Tumor Type | colorectal cancer |
n/a |
combination therapy | Trastuzumab + Lapatinib |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | decreased response |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase p110-alpha subunit inhibitor |
Direct Interaction | yes |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
Response Type | no benefit |
combination therapy | Alpelisib + WEHI-539 |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
combination therapy | BGJ398 + GDC-0941 |
combination therapy | GDC-0941 + Linsitinib |
combination therapy | GDC-0941 + NVP-AEW541 |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
combination therapy | Buparlisib + Fulvestrant |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Reported Cancer Type | Melanoma |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Indication/Tumor Type | colon cancer |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase p110-alpha subunit inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase p110-alpha subunit inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
n/a |
Novel drug target | Novel Target |
Trial Name | ON 01910.Na,Estybon |
Indication/Tumor Type | head and neck squamous cell carcinoma |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | prostate cancer |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Reported Cancer Type | Melanoma |
inhibitor (inhibitory) |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | Advanced Solid Tumor |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Indication/Tumor Type | breast adenocarcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | colorectal cancer |
inhibitor (inhibitory) |
Indication/Tumor Type | ovarian clear cell adenocarcinoma |
Response Type | sensitive |
Approval Status | Preclinical - Cell culture |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Response Type | no benefit |
Indication/Tumor Type | renal cell carcinoma |
Indication/Tumor Type | malignant pleural mesothelioma |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Phase I |
Response Type | no benefit |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Preclinical |
Response Type | sensitive |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Indication/Tumor Type | colon adenocarcinoma |
Indication/Tumor Type | breast cancer |
Evidence Type | Actionable |
inhibitor (inhibitory) |
Indication/Tumor Type | hematologic cancer |
Approval Status | Preclinical - Cell line xenograft |
Indication/Tumor Type | Advanced Solid Tumor |
n/a |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted – sensitive |
Approval Status | Phase I |
inhibitor (inhibitory) |
combination therapy | AZD6482 + BYL719 |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
inhibitor (inhibitory) |
combination therapy | PI-103 + 5-FU |
Indication/Tumor Type | gastric adenocarcinoma |
Response Type | sensitive |
inhibitor (inhibitory) |
combination therapy | BGJ398 + BKM120 |
combination therapy | BGJ398 + BYL719 |
Evidence Type | Actionable |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
PIK3CA | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
PIK3CA | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.1.153 |
PIK3CA | Uniprot Gene Name |
ENSG00000121879 | Ensembl Gene Id |
PK3CA_HUMAN | Uniprot Id |
Interpro Short Name | PI3/4_kinase_cat_dom |
Human Readable Name | PHOSPHATIDYLINOSITOL 3 KINASE |
Uniprot Evidence | 1: Evidence at protein level |
DRUGGABLE GENOME, PHOSPHATIDYLINOSITOL 3 KINASE |
5290 | Entrez Gene ID |
5289 | Entrez Gene ID |
CancerCommons Reported Gene Name | PI3K |
CancerCommons Reported Gene Name | PI3K/mTOR |
PIK3CA | Display Id |
PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT, ALPHA ISOFORM (EC 2.7.1.153) (PI3-KINASE P110 SUBUNIT ALPHA) (PTDINS- 3-KINASE P110) (PI3K). [SOURCE:UNIPROT/SWISSPROT;ACC:P42336] | Description |
ENSG00000121879 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
5290 | CKB Entrez Id |
PIK3CA | CKB Gene Synonym |
CLOVE | CKB Gene Synonym |
PA33308 | PharmGKB ID |
5290 | Entrez Gene ID |
37 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
5290 | Entrez Gene Id |
PIK3CA | MyCancerGenome Gene Symbol |
PI3K | MyCancerGenome Reported Gene Name |
PIK3CA | GENE_SYMBOL |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | UNIPROT |
Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha | UNIPROT |
ENSG00000121879 | Gene Symbol |
PIK3CA | Ensembl Id |
DRUGGABLE GENOME |
5290 | OncoKB Entrez Id |
MCAP | OncoKB Gene Synonym |
p110-alpha | OncoKB Gene Synonym |
PIK3CA | Gene Symbol |
CLINICALLY ACTIONABLE |
5290 | Gene ID |
PI3K | dGene Synonym |
p110-alpha | dGene Synonym |
KINASE, PHOSPHATIDYLINOSITOL 3 KINASE |
PIK3CA | TTD Gene Abbreviation |
T80276 | TTD Target ID |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Gene Name |
P42336 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
KINASE, SERINE THREONINE KINASE |
CLINICALLY ACTIONABLE |